Article
A pharmacogenetic signature of high response to Copaxone in late-phase clinical-trial cohorts of multiple sclerosis.
Genome medicine - 31 May 2017
Ross Colin J, Towfic Fadi, Shankar Jyoti, Laifenfeld Daphna, Thoma Mathis, Davis Matthew, Weiner Brian, Kusko Rebecca, Zeskind Ben, Knappertz Volker, Grossman Iris, Hayden Michael R
Abstract excerpt
BACKGROUND: Copaxone is an efficacious and safe therapy that has demonstrated clinical benefit for over two decades in patients with relapsing forms of multiple sclerosis (MS). On an individual level, patients show variability in their response to Copaxone, with some achieving significantly higher response levels. The involvement of genes (e.g., HLA-DRB1*1501) with high inter-individual variability in Copaxone's...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.